{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:40:06Z","timestamp":1769164806247,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ahj.2013.10.028","type":"journal-article","created":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T13:00:36Z","timestamp":1387544436000},"page":"413-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans"],"prefix":"10.1016","volume":"167","author":[{"given":"Julie H.","family":"Oestreich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyle G.","family":"Best","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul P.","family":"Dobesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2013.10.028_bb0120","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2013.10.028_bb0010","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2013.10.028_bb0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.10.028_bb0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.amjcard.2003.10.042","article-title":"Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization","volume":"93","author":"Mobley","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2013.10.028_bb0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.10.028_bb0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.10.028_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrcardio.2009.10","article-title":"Antiplatelet drug \u201cresistance\u201d. Part 1: mechanisms and clinical measurements","volume":"6","author":"Sweeny","year":"2009","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2013.10.028_bb0040","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.10.028_bb0045","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/0091270009343005","article-title":"Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans","volume":"50","author":"Farid","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2013.10.028_bb0050","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2013.10.028_bb0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.10.028_bb0060","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Pare","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.10.028_bb0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2013.10.028_bb0070","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1146\/annurev.pharmtox.41.1.815","article-title":"Molecular basis of ethnic differences in drug disposition and response","volume":"41","author":"Xie","year":"2001","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ahj.2013.10.028_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00008571-199608000-00006","article-title":"CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population","volume":"6","author":"Jurima-Romet","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ahj.2013.10.028_bb0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0009-9236(98)90068-6","article-title":"Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies","volume":"64","author":"Nowak","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2013.10.028_bb0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/FPC.0b013e3283629ce9","article-title":"Pharmacogenetics in Native American populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes","volume":"23","author":"Fohner","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ahj.2013.10.028_bb0090","first-page":"e6","article-title":"Heart disease and stroke statistics\u20142013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2013.10.028_bb0095","unstructured":"VerifyNow Aspirin Test Instructions for Use. April 28, 2011. April 28, 2011. http:\/\/www.accumetrics.com\/dmdocuments\/Aspirin\/VN-PackageInsert_Aspirin.pdf. [accessed July 19, 2013]."},{"key":"10.1016\/j.ahj.2013.10.028_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/MCA.0b013e328329924b","article-title":"Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel","volume":"20","author":"Oestreich","year":"2009","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.ahj.2013.10.028_bb0105","article-title":"ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention","volume":"2011","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2013.10.028_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/jth.12059","article-title":"Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis","volume":"11","author":"Lala","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2013.10.028_bb0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/j.1875-9114.2012.01048","article-title":"Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel","volume":"32","author":"Reese","year":"2012","journal-title":"Pharmacotherapy"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031300834X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031300834X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:51:55Z","timestamp":1757569915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031300834X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S000287031300834X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2013.10.028","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2013.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}